eyecro and NeuMedics announce collaboration to utilize MiDROPS™ technology for the development of NM108

ByConnor Hodde

Oklahoma City, OK, and Seattle, WA; (May 4, 2015) – eyecro LLC and NeuMedics Inc., today announced the formation of a collaboration to facilitate development of NM108, a first-in-class small molecule to treat a number of ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. The collaboration grants NeuMedics full access to the MiDROPS™ formulation platform developed by eyecro, which can deliver drugs to the front and back of the eye via a topical eyedrop.

Read the entire article here.

Similar Posts

New Polymer Allows Improved Method for Preparation of Nanoparticles for Drug Delivery

ByConnor Hodde

Ainhoa Lejardi, an engineer at the UPV/EHU, has created a new polymer material which could improve the preparation of nanospheres for their use as a method of controlling the release of pharmaceuticals, research which is currently ongoing at the Consejo Superior de Investigaciones Científicas (CSIC) (Spanish National Research Council) in Madrid. http://www.azonano.com/news.aspx?newsID=24876

Rosemary Compound Shown To Help Fight Macular Degeneration In Mouse Model

ByConnor Hodde

A new study led by the Sanford-Burnham Medical Research Institute reports that carnosic acid, found in the herb rosemary, actually promotes eye health. Led by Dr. Stuart A. Lipton, the team found that carnosic acid protects the retina from degeneration and toxicity in cell culture and in rodent models of light-induced retinal damage. This suggests…

Proteomic Studies of Age-Related Ocular Diseases

ByConnor Hodde

A Cleveland Clinic lab has found evidence to support the theory that age-related macular degeneration (AMD) is an inflammatory disease with varying ways to progress to advanced dry and wet AMD.  Focusing on proteomic studies to discover biomarkers and molecular mechanisms of AMD and glaucoma, John W. Crabb, PhD, and his colleagues found many proteins…

Pharma News: Bayer, Johns Hopkins partner to develop new ophthalmic therapies

ByConnor Hodde

Bayer HealthCare has entered into a five-year collaboration agreement with The Johns Hopkins University in Baltimore, US, for the discovery and development of new therapies in ophthalmology targeting retinal diseases.  Both the parties will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet…

Roche CEO ‘sleeps better’ as risk to drugmaker’s growth recedes

ByConnor Hodde

LONDON (Reuters) – Roche (ROG.S) is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker’s older cancer medicines start to grab business next year, its chief executive said on Wednesday. In February the company won U.S. Food and Drug Administration (FDA) breakthrough status for new multiple…